Online inquiry

IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4046MR)

This product GTTS-WQ4046MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL36RN gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_012275.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 26525
UniProt ID Q9UBH0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4046MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6688MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ4267MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ13460MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ7371MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ8498MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ15756MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ2043MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ13941MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-2810
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW